NCT02509884

Brief Summary

Comprehensive diagnosis and treatment of Alveolar Echinococcosis : A single-center, long-term observational study of 312 Patients in Germany. Human alveolar echinococcosis (AE) is the most Iethal human helminthic infection and is one of the 17 neglected tropical diseases prioritized by the World Health Organization (WHO). Its incidence is low in endemic regions of Central and Western Europe (0.03-0.05/100,000), but morbidity and treatment costs are high. In this observational study, the investigators assessed the severity of the disease using the PNM staging system and report on the long-term results of specific AE therapy in an interdisciplinary team of clinicians.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
312

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 1992

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 1992

Completed
19.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

July 12, 2015

Completed
16 days until next milestone

First Posted

Study publicly available on registry

July 28, 2015

Completed
Last Updated

July 28, 2015

Status Verified

July 1, 2015

Enrollment Period

19.9 years

First QC Date

July 12, 2015

Last Update Submit

July 27, 2015

Conditions

Keywords

Alveolar Echinococcosis (AE)Echinococcus multilocularisantiparasitic treatmentsurgeryclassificationstagingprospective cohort study

Outcome Measures

Primary Outcomes (3)

  • Overall survival after diagnosis,

    Survival was estimated by the Kaplan Meier method.

    inclusion January 1992-December 2011; end of follow-up December 2012 .Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)

  • Relapse after surgery or progression of remaining liver lesions in size or new lesions in other organs

    Parameters with an assumed influence on the time until relapse or progress of the parasitic lesions entered Kaplan Meier survival analysis and Cox proportional hazard regression model analysis, respectively, and hazard ratios (HR) with corresponding 95% confidence intervals (CI) were calculated.

    inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)

  • Time to relapse or progress

    inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)

Secondary Outcomes (4)

  • Symptoms and comorbidities

    inclusion January 1992-December 2011; end of follow-up December 2012. Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)

  • Medical treatment and side effects

    inclusion January 1992-December 2011; end of follow-up December 2012Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)

  • Treatment interruption ant potential cure

    inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)

  • Surgical and interventional treatment

    inclusion January 1992-December 2011; end of follow-up December 2012.Inclusion January 1992-December 1999 (series A).Inclusion January 2000- December 2011 (series B)

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients with AE seen at the specialized treatment unit in Ulm between January 1992 and December 2011 were included in the database. Follow-up ended on 31.12.2012. Cases were defined according to the likelihood of diagnosis as a "possible", "probable", or "confirmed case"

You may qualify if:

  • All patients with AE seen at the specialized treatment unit in Ulm between January 1992 and December 2011.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Kern P, Wen H, Sato N, Vuitton DA, Gruener B, Shao Y, Delabrousse E, Kratzer W, Bresson-Hadni S. WHO classification of alveolar echinococcosis: principles and application. Parasitol Int. 2006;55 Suppl:S283-7. doi: 10.1016/j.parint.2005.11.041. Epub 2005 Dec 15.

    PMID: 16343985BACKGROUND
  • Brunetti E, Kern P, Vuitton DA; Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 2010 Apr;114(1):1-16. doi: 10.1016/j.actatropica.2009.11.001. Epub 2009 Nov 30.

    PMID: 19931502BACKGROUND

MeSH Terms

Conditions

Alveolar echinococcosisEchinococcosis

Condition Hierarchy (Ancestors)

Cestode InfectionsHelminthiasisParasitic DiseasesInfections

Study Officials

  • Beate Grüner, MD

    University of Ulm

    STUDY CHAIR

Study Design

Study Type
observational
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Beate Grüner, MD

Study Record Dates

First Submitted

July 12, 2015

First Posted

July 28, 2015

Study Start

January 1, 1992

Primary Completion

December 1, 2011

Study Completion

December 1, 2012

Last Updated

July 28, 2015

Record last verified: 2015-07